Catalent (NYSE:CTLT – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report ...

Catalent, Inc. CTLT reported first-quarter fiscal 2025 adjusted loss per share of 13 cents, flat year over year. The figure ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Catalent (CTLT – Research Report), Moderna (MRNA – Research ...

Catalent (CTLT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.11. This compares to loss of $0.10 per share a year ago. These figures are adjusted for ...

Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50.

Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have been given a consensus rating of “Hold” by the eight ratings firms that are presently covering the stock, MarketBeat reports. Eight ...

Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...

Here is how Cardiol Therapeutics Inc. (CRDL) and Catalent (CTLT) have performed compared to their sector so far this year. Maselli's open letter comes on the back of criticism over Novo Holding's ...

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive ...